Flinton Capital Management LLC boosted its position in BIO-TECHNE Corp (NASDAQ:TECH) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,248 shares of the biotechnology company’s stock after acquiring an additional 80 shares during the period. Flinton Capital Management LLC’s holdings in BIO-TECHNE were worth $470,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in BIO-TECHNE by 2.3% in the fourth quarter. BlackRock Inc. now owns 3,855,948 shares of the biotechnology company’s stock worth $558,034,000 after acquiring an additional 85,590 shares in the last quarter. Vanguard Group Inc. boosted its holdings in BIO-TECHNE by 2.4% in the third quarter. Vanguard Group Inc. now owns 3,361,425 shares of the biotechnology company’s stock worth $686,101,000 after acquiring an additional 77,626 shares in the last quarter. Vanguard Group Inc boosted its holdings in BIO-TECHNE by 2.4% in the third quarter. Vanguard Group Inc now owns 3,361,425 shares of the biotechnology company’s stock worth $686,101,000 after acquiring an additional 77,626 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in BIO-TECHNE by 18.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 803,633 shares of the biotechnology company’s stock worth $116,303,000 after acquiring an additional 125,665 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in BIO-TECHNE by 11.1% in the fourth quarter. First Trust Advisors LP now owns 747,827 shares of the biotechnology company’s stock worth $108,226,000 after acquiring an additional 74,863 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

A number of research analysts have recently weighed in on TECH shares. Stephens upgraded BIO-TECHNE from an “equal weight” rating to an “overweight” rating and set a $180.00 target price on the stock in a report on Monday, January 14th. Zacks Investment Research upgraded BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Wednesday, November 28th. BidaskClub upgraded BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Craig Hallum restated a “hold” rating and issued a $179.00 target price (up previously from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Finally, ValuEngine upgraded BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 5th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. BIO-TECHNE presently has an average rating of “Buy” and an average price target of $188.13.

TECH stock opened at $194.52 on Friday. BIO-TECHNE Corp has a twelve month low of $132.75 and a twelve month high of $206.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.31 and a current ratio of 4.35. The company has a market capitalization of $7.30 billion, a PE ratio of 47.79, a P/E/G ratio of 4.37 and a beta of 1.25.

BIO-TECHNE (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $0.98 by $0.08. The business had revenue of $174.50 million for the quarter, compared to analyst estimates of $171.39 million. BIO-TECHNE had a return on equity of 13.90% and a net margin of 14.02%. BIO-TECHNE’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same period last year, the company posted $1.02 earnings per share. Equities research analysts anticipate that BIO-TECHNE Corp will post 3.68 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 1st. Investors of record on Friday, February 15th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, February 14th. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. BIO-TECHNE’s dividend payout ratio (DPR) is currently 31.45%.

COPYRIGHT VIOLATION WARNING: “Flinton Capital Management LLC Purchases 80 Shares of BIO-TECHNE Corp (TECH)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2019/03/15/flinton-capital-management-llc-purchases-80-shares-of-bio-techne-corp-tech.html.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

See Also: Different Options Trading Strategies

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.